Peel Hunt Reaffirms Add Rating for Clinigen Group PLC (CLIN)
Peel Hunt reiterated their add rating on shares of Clinigen Group PLC (LON:CLIN) in a research report released on Wednesday morning. Peel Hunt currently has a GBX 1,200 ($15.50) target price on the stock.
CLIN has been the subject of a number of other research reports. Numis Securities Ltd cut shares of Clinigen Group PLC to an add rating and set a GBX 1,100 ($14.21) price objective for the company. in a research report on Tuesday, July 18th. Stifel Nicolaus restated a buy rating and issued a GBX 970 ($12.53) price objective on shares of Clinigen Group PLC in a research report on Monday, May 22nd.
Shares of Clinigen Group PLC (LON:CLIN) opened at 1027.00 on Wednesday. Clinigen Group PLC has a 52-week low of GBX 646.50 and a 52-week high of GBX 1,149.00. The firm’s market cap is GBX 1.18 billion. The company’s 50-day moving average price is GBX 1,060.82 and its 200-day moving average price is GBX 907.48.
COPYRIGHT VIOLATION WARNING: “Peel Hunt Reaffirms Add Rating for Clinigen Group PLC (CLIN)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/16/peel-hunt-reaffirms-add-rating-for-clinigen-group-plc-clin.html.
In other Clinigen Group PLC news, insider John Bacon sold 200,000 shares of the stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of GBX 843 ($10.89), for a total transaction of £1,686,000 ($2,177,450.60). Also, former CEO Peter George sold 500,000 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of GBX 875 ($11.30), for a total value of £4,375,000 ($5,650,264.76).
Clinigen Group PLC Company Profile
Receive News & Stock Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related stocks with our FREE daily email newsletter.